Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deep Response in Multiple Myeloma: A Critical Review.
Fulciniti M, Munshi NC, Martinez-Lopez J. Fulciniti M, et al. Biomed Res Int. 2015;2015:832049. doi: 10.1155/2015/832049. Epub 2015 Dec 10. Biomed Res Int. 2015. PMID: 26783530 Free PMC article. Review.
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC. Xu Y, et al. Among authors: fulciniti m. Blood. 2020 Jul 23;136(4):468-479. doi: 10.1182/blood.2019004147. Blood. 2020. PMID: 32187357 Free PMC article.
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Soncini D, Martinuzzi C, Becherini P, Gelli E, Ruberti S, Todoerti K, Mastracci L, Contini P, Cagnetta A, Laudisi A, Guolo F, Minetto P, Miglino M, Aquino S, Varaldo R, Reverberi D, Formica M, Passalacqua M, Nencioni A, Neri A, Samur MK, Munshi NC, Fulciniti M, Lemoli RM, Cea M. Soncini D, et al. Among authors: fulciniti m. Haematologica. 2022 Jun 1;107(6):1410-1426. doi: 10.3324/haematol.2021.279276. Haematologica. 2022. PMID: 34670358 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: fulciniti m. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605 Free PMC article.
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. Yao Y, et al. Among authors: fulciniti m. Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885. Blood. 2023. PMID: 36877894 Free PMC article.
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
Deng S, Derebail S, Weiler VJ, Fong Ng J, Maroto-Martin E, Chatterjee M, Giorgetti G, Chakraborty C, Kalhotra P, Du T, Yao Y, Prabhala R, Shammas M, Gulla A, Aktas Samur A, Samur MK, Qiu L, Anderson KC, Fulciniti M, Munshi NC. Deng S, et al. Among authors: fulciniti m. Blood Adv. 2024 Aug 13;8(15):4025-4034. doi: 10.1182/bloodadvances.2023012298. Blood Adv. 2024. PMID: 38861273 Free PMC article.
102 results